CATUVAB® is based on the formation of cell aggregates comprised of EpCAM positive tumor cells, lymphocytes and accessory immune cells.
CATUVAB® contains a trifunctional antibody designed to bind and aggregate EpCAM-positive tumor cells and immune cells. These cell complexes are subsequently removed during intraoperative blood salvage. Each kit enables treatment of up to 3 liters of salvaged blood.
The included buffer solution supports optimal antibody activity and is used in conjunction with standard Intraoperative Blood Salvage (IBS/ICS) devices (e.g., Cell Saver systems). It ensures compatibility with routine surgical workflows.
The single-use CATUVAB® kit includes all required sterile syringes and components for safe and efficient application. Designed for seamless integration into standard IBS procedures during EpCAM-positive solid tumor surgeries.
The technology behind CATUVAB isour innovative proprietary and patented Antibody-Based Cell Removal Technology (ABCR-T).
The aggregation of cells is mediated by an aggregating agent, a trifunctional bispecific antibody.
The trifunctional antibody binds to tumor and immune cells in the blood.
Bound cells cluster together, forming larger cell aggregates.
The aggregates are efficiently removed using standard separation techniques, e.g. filtration.
The formation of the aggregates takes place extracorporeally, after the antibody is added to of salvaged operational blood that has been collected in a reservoir of the IBS device during tumor surgery.
All efficacy endpoints were met with high statistical significance.
In 60 patients with tumor cell–positive blood, 59 had zero residual tumor cells after CATUVAB® treatment.
One patient had only 4 remaining tumor cells.
Up to 4.2 million tumor cells were removed in some cases.
Multi-center study across 6 sites
136 patients evaluated
80 re-transfusions of erythrocyte concentrates
Study endpoints: tumor cell removal, cytokine levels, residual antibody assessments
CE-marked and manufactured under MDR & ISO 13485
Compatible with standard cell saver systems for seamless OR integration
The majority of solid tumors are EpCAM positive of which over 6.4M patients require surgical intervention per year, representing an addressable patient pool for CATUVAB®.
Adults with an EpCAM-positive malignancy (e.g., tumors with EpCAMpositivity ≥ 92%), where an autologoustransfusion is medically appropriate.
CATUVAB® is compatible with surgeries involving tumors with a high EpCAM+ probability, which are prevalent across many leading cancer types – including breast, colorectal, lung, pancreatic, and prostate cancers.
Autologous blood is immediately available during surgery, eliminating the need for crossmatching or blood bank logistics - especially valuable in urgent oncologic procedures.
By using the patient’s own blood, CATUVAB® significantly lowers the risk of transfusion-transmitted infections and immunologic reactions compared to donor blood.
Autologous transfusion removes the need for blood type compatibility, simplifying perioperative care and reducing procedural complexity.
CATUVAB® enables intraoperative reuse of patient blood, reducing dependency on donor blood supply and lowering overall treatment and storage costs.
